HSK39297 tablets

DRUG4 trials

Sponsors

Haisco Pharmaceutical Group Co., Ltd.

Conditions

PNHParoxysmal Nocturnal Haemoglobinuria (PNH)Paroxysmal Nocturnal HemoglobinuriaParoxysmal Nocturnal Hemoglobinuria (PNH)

Phase 1

Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HSK39297 in Subjects With Hepatic Impairment

RecruitingNCT07152288

Haisco Pharmaceutical Group Co., Ltd.Paroxysmal Nocturnal Hemoglobinuria (PNH)

Start: 2025-05-29End: 2025-11-30Target: 24Updated: 2025-09-03

Phase 2

Long-term Safety and Tolerability of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria

RecruitingNCT06745622

Haisco Pharmaceutical Group Co., Ltd.Paroxysmal Nocturnal Hemoglobinuria

Start: 2025-01-03End: 2027-06-30Target: 47Updated: 2024-12-20

Phase 3

A Phase III Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy

CompletedNCT06799546

Haisco Pharmaceutical Group Co., Ltd.PNH

Start: 2025-02-13End: 2025-11-05Updated: 2025-12-22

Efficacy and Safety of HSK39297 in Anti-C5 Treated PNH Patients With Anemia

CompletedNCT07052838

Haisco Pharmaceutical Group Co., Ltd.Paroxysmal Nocturnal Haemoglobinuria (PNH)

Start: 2025-05-12End: 2026-01-05Updated: 2026-02-11